Shots:
- Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in Shoreline’s recent Series A financing
- The collaboration will utilize Shoreline’s iPSC differentiation and genetic reprogramming with Kite’s cell therapy to develop novel allogeneic therapies for hematologic malignancies
- Initially, the collaboration will focus on CAR NK targets, with Kite having an option to expand the collaboration to include an iPSC CAR Macrophage program for an undisclosed target to be selected post deal execution
Click here to read full press release/ article | Ref: Gilead | Image: Glassdoor
The post Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies first appeared on PharmaShots.
